Last edition
News about "John Kane"
Teva's UZEDY Outperforms LAIs in Schizophrenia Care
Teva Pharmaceuticals shows new real-world data showing UZEDY outperforms other Long-Acting Injectables in treatment adherence, reducing ER visits and costs.
John Kane | 21/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members